Oncotarget

Research Papers:

This article has been corrected. Correction in: Oncotarget. 2019; 10:1010.

Ocular toxicities associated with targeted anticancer agents: an analysis of clinical data with management suggestions

Chen Fu, Dan S. Gombos, Jared Lee, Goldy C. George, Kenneth Hess, Andrew Whyte and David S. Hong _

PDF  |  HTML  |  How to cite  |  Order a Reprint

Oncotarget. 2017; 8:58709-58727. https://doi.org/10.18632/oncotarget.17634

Metrics: PDF 1612 views  |   HTML 3058 views  |   ?  


Abstract

Chen Fu1, Dan S. Gombos5, Jared Lee2, Goldy C. George3, Kenneth Hess4, Andrew Whyte5 and David S. Hong3

1Department of Internal Medicine, New York University Langone Medical Center, NY 10016, USA

2Department of Internal Medicine, Baylor College of Medicine, TX 77030, USA

3Department of Phase I Clinical Trials, The University of Texas MD Anderson Cancer Center, TX 77030, USA

4Department of Biostatistics, The University of Texas MD Anderson Cancer Center, TX 77030, USA

5Department of Head and Neck Surgery, Division of Ophthalmology, The University of Texas MD Anderson Cancer Center, TX 77030, USA

Correspondence to:

David S. Hong, email: dshong@mdanderson.org

Keywords: targeted, cancer, ocular, toxicity, management

Received: September 20, 2016    Accepted: March 16, 2017    Published: May 05, 2017

ABSTRACT

Ocular toxicities are among the most common adverse events resulting from targeted anticancer agents and are becoming increasingly relevant in the management of patients on these agents. The purpose of this study is to provide a framework for management of these challenging toxicities based on objective data from FDA labels and from analysis of the literature. All oncologic drugs approved by the FDA up to March 14, 2015, were screened for inclusion. A total of 16 drugs (12 small-molecule drugs and 4 monoclonal antibodies) were analyzed for ocular toxicity profiles based on evidence of ocular toxicity. Trials cited by FDA labels were retrieved, and a combination search in Medline, Google Scholar, the Cochrane database, and the NIH Clinical Trials Database was conducted. The majority of ocular toxicities reported were low severity, and the most common were conjunctivitis and “visual disturbances.” However, severe events including incidents of blindness, retinal vascular occlusion, and corneal ulceration occurred. The frequency and severity at which ocular toxicities occur merits a more multidisciplinary approach to managing patients with agents that are known to cause ocular issues. We suggest a standardized methodology for referral and surveillance of patients who are potentially at risk of severe ocular toxicity.


Creative Commons License All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 3.0 License.
PII: 17634